IBDEI0XZ ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16775,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,16776,0)
 ;;=070.51^^92^941^29
 ;;^UTILITY(U,$J,358.3,16776,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16776,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,16776,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,16776,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,16777,0)
 ;;=070.54^^92^941^30
 ;;^UTILITY(U,$J,358.3,16777,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16777,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,16777,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,16777,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,16778,0)
 ;;=571.41^^92^941^32
 ;;^UTILITY(U,$J,358.3,16778,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16778,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,16778,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,16778,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,16779,0)
 ;;=571.1^^92^941^33
 ;;^UTILITY(U,$J,358.3,16779,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16779,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,16779,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,16779,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,16780,0)
 ;;=070.59^^92^941^34
 ;;^UTILITY(U,$J,358.3,16780,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16780,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,16780,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,16780,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,16781,0)
 ;;=V08.^^92^941^24
 ;;^UTILITY(U,$J,358.3,16781,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16781,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,16781,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,16781,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,16782,0)
 ;;=042.^^92^941^25
 ;;^UTILITY(U,$J,358.3,16782,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16782,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,16782,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,16782,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,16783,0)
 ;;=464.00^^92^941^2
 ;;^UTILITY(U,$J,358.3,16783,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16783,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,16783,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,16783,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,16784,0)
 ;;=790.6^^92^941^1
 ;;^UTILITY(U,$J,358.3,16784,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16784,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,16784,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,16784,2)
 ;;=^87228
 ;;^UTILITY(U,$J,358.3,16785,0)
 ;;=780.60^^92^941^20
 ;;^UTILITY(U,$J,358.3,16785,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16785,1,4,0)
 ;;=4^780.60
 ;;^UTILITY(U,$J,358.3,16785,1,5,0)
 ;;=5^Fever
 ;;^UTILITY(U,$J,358.3,16785,2)
 ;;=^336764
 ;;^UTILITY(U,$J,358.3,16786,0)
 ;;=795.51^^92^941^55
 ;;^UTILITY(U,$J,358.3,16786,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16786,1,4,0)
 ;;=4^795.51
 ;;^UTILITY(U,$J,358.3,16786,1,5,0)
 ;;=5^Pos PPD w/o Active TB
 ;;^UTILITY(U,$J,358.3,16786,2)
 ;;=^340572
 ;;^UTILITY(U,$J,358.3,16787,0)
 ;;=482.9^^92^941^53
 ;;^UTILITY(U,$J,358.3,16787,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16787,1,4,0)
 ;;=4^482.9
 ;;^UTILITY(U,$J,358.3,16787,1,5,0)
 ;;=5^Pneumonia,Bacterial
 ;;^UTILITY(U,$J,358.3,16787,2)
 ;;=^12347
 ;;^UTILITY(U,$J,358.3,16788,0)
 ;;=571.42^^92^941^31
 ;;^UTILITY(U,$J,358.3,16788,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16788,1,4,0)
 ;;=4^571.42
 ;;^UTILITY(U,$J,358.3,16788,1,5,0)
 ;;=5^Hepatitis, Autoimunne
 ;;^UTILITY(U,$J,358.3,16788,2)
 ;;=^336610
 ;;^UTILITY(U,$J,358.3,16789,0)
 ;;=795.52^^92^941^54
 ;;^UTILITY(U,$J,358.3,16789,1,0)
 ;;=^358.31IA^5^2
